Appointment of Non-Executive Director

RNS Number : 7404J

Venture Life Group PLC

17 June 2014

 



Venture Life Group plc

("Venture Life" or "the Group")

Appointment of Non-Executive Director

Bracknell, UK - 17 June 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces the appointment of Ian Mackinnon to the board as a non-executive director with effect from 16 June 2014. He will chair the Group's Audit and Risk Committee and will also be a member of the Remuneration and Nomination Committees. John Sylvester, who currently chairs the Group's Audit and Risk Committee will be standing down as chair of this committee but will remain a member.

Mr Mackinnon was formerly the Chief Financial Officer and Chief Executive Officer of Swallowfield plc, a leading supplier to global brands in the cosmetics, personal care and household goods sectors.  He is also a Fellow of the Institute of Chartered Accountants of England and Wales.

Dr Lynn Drummond, Chair of Venture Life said: "I am pleased to welcome Ian to the board of Venture Life. Ian's experience, particularly of commercial operations in the Far East, will be invaluable as we grow both our brands and manufacturing businesses. We look forward to his contribution to the board."

Ian Mackinnon added "I am excited to be joining this ambitious company and working with it as it executes its growth strategy."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Ian Andrew Mackinnon, age 49 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

IM Advisory Limited

Past directorships

Swallowfield plc and various subsidiaries

Mr Mackinnon has not held any other directorships in the previous five years and he does not hold any ordinary shares in the Group. There are no further disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules in connection with Ian Mackinnon's appointment to the Group's Board.

- Ends -

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer                                   [phone]

WG Partners (Broker)          
Jonathan Gosling

Claes Spång                                                                           [phone]

Charles Stanley Securities (Nominated Adviser)  
Phil Davies                                                                              [phone]

Square1 Consulting

David Bick

Mark Longson                                                                         [phone]

JW Communications

Julia Wilson                                                                             [phone]

Notes to editors

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently includes food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

·     food supplements to maintain brain function and memory;

·     dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

·     medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

END

 

 

BOAEQLFFZQFFBBQ